Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about June 10, 2026, to redeem the remaining common stock warrants issued by the Company as part of its July 3, 2024 rights offering. These outstanding common stock warrants (the “200% Warrants”), which were issued in the Company’s 2024 rights offering (the “Rights Offering”), pursuant to the Company’s Registration Statement on Form S-3, as amended (File No. 333-278494), may be exercised by the holders thereof until 5:00 p.m., Eastern time, on July 13, 2026, at the exercise price of $11.00 per share of Company common stock, $0.001 par value per share. Any 200% Warrants not exercised before 5:00 p.m., Eastern time, on July 13, 2026 (the “Redemption Date”), will be redeemed by the Company for $0.01 per 200% Warrant share (the “Redemption Price”).
Under the terms of the 200% Warrants, the Company has the right to redeem the 200% Warrants (CUSIP # 74587B143) if the volume weighted average price (as defined therein, “VWAP”) exceeds $22.00 per share for twenty (20) consecutive trading days at least three months after the date that the 200% Warrants were issued. This requirement was met for each of the twenty consecutive trading days preceding June 10, 2026. Over this period, the Company had an average VWAP of $25.17.
